Ethyol Approved for Use in the UK

January 1, 1995

Publication

Article

Oncology NEWS InternationalOncology NEWS International Vol 4 No 1

Volume 4

Issue 1

WEST CONSHOHOCKEN, Pa--The Medicines Control Agency, the regulatory agency for the United Kingdom, has granted a product license for the marketing of Ethyol (amifostine), manufactured by U.S. Bioscience, Inc.

WEST CONSHOHOCKEN, Pa--The Medicines Control Agency, the regulatoryagency for the United Kingdom, has granted a product license forthe marketing of Ethyol (amifostine), manufactured by U.S. Bioscience,Inc.

Ethyol is a selective cytoprotective agent indicated for the reductionof neutropenia-related infection resulting from use of the combinationof cyclophosphamide (Cytoxan, Neosar) and cisplatin (Platinol)in patients with advanced ovarian carcinoma.

Approval of ethyol in this country suffered a set back when anadvisory committee failed to recommend it to the FDA.

Articles in this issue

MDs Fear Managed Care Equals Lower-Quality Care

Dallas Medical Center Launches Umbilical Stem Cell Project

Navelbine Receives FDA Approval for Advanced Non-Small -Cell Lung Cancer

European Trials Show Dose-Related Efficacy of Docetaxel In Metastatic Breast Cancer, Value of Steroid Pretreatment

Ethyol Approved for Use in the UK

Success of Breast Conserving Surgery Is Not Diminished in Community Setting

Assessment Tools Are Essential to Improve Management of Pain

Undertreating Pain Costs Money in the Long Run, Physician Warns

After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCI

EORTC Endometrial Ca Trial Challenges Findings From GOG

Heterosexual AIDS Cases Up Sharply, But Numbers Remain Small

Antibiotic Regimen Leads to Lymphoma Regression

Look for Incremental Insurance Reform Steps With New Congress

Court Upholds Patents on AZT

Advances Reported in Phase I/II Trials of Radioimmunotherapy for Breast Cancer

Recent Videos

2 experts in this video

2 experts in this video

Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,

Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.

The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.

Related Content

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Patients who received 70 Gy of radiotherapy had a significantly longer duration of treatment than those who received less than 70 Gy.

High-Dose CCRT Plus Durvalumab May Be Safe, Efficacious in Stage III NSCLC

Roman Fabbricatore

Patients who received 70 Gy of radiotherapy had a significantly longer duration of treatment than those who received less than 70 Gy.

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild-to-moderate severity.

PROs Support Safety of Durvalumab Plus Platinum/Etoposide in ES-SCLC

Roman Fabbricatore

Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild-to-moderate severity.

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD

Related Content

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Patients who received 70 Gy of radiotherapy had a significantly longer duration of treatment than those who received less than 70 Gy.

High-Dose CCRT Plus Durvalumab May Be Safe, Efficacious in Stage III NSCLC

Roman Fabbricatore

Patients who received 70 Gy of radiotherapy had a significantly longer duration of treatment than those who received less than 70 Gy.

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild-to-moderate severity.

PROs Support Safety of Durvalumab Plus Platinum/Etoposide in ES-SCLC

Roman Fabbricatore

Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild-to-moderate severity.

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.